Significant weight gain seen during first year of postprostatectomy ADT

Share this content:

In a group of men who underwent androgen-deprivation therapy (ADT) after radical prostatectomy, the majority gained significant weight during the first year of treatment, but not thereafter.

The 132 men analyzed for the study were identified through a cancer-hospital database. Prior research has shown that men receiving ADT tend to lose lean muscle and increase fat mass. In this project, 92 (70%) of the men gained weight, and 40 (30%) either lost weight or maintained a stable weight. The gainers put on an average of 4.2 kg (9.26 lbs); the losers lost an average of 2.4 kg (5.3 lbs).

These changes in weight compared with no significant weight change in the year before starting ADT or in the second year on ADT for 84 men in whom these additional weight values were recorded.

No demographic, clinical, or pathologic differences existed between the gainers and the losers.

“While ADT has been a mainstay treatment for recurrent or metastatic prostate cancer, physicians are increasing the use of ADT to treat localized disease,” explained Stephen J. Freedland, MD, of the Duke Prostate Center at Duke University School of Medicine (Durham, North Carolina), and colleagues in BJU International (2011;107[6]:924-928; “This rising utilization of ADT warrants a closer examination of the side-effects of therapy, which include metabolic changes that potentially contribute to an increased incidence of diabetes and perhaps other comorbidities.”

The authors added that their findings as well as the results of previous studies suggest that the ADT-related weight changes take place within the first year of therapy and persist thereafter, but do not necessarily continue to worsen over time.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs